 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > OXiGENE, Inc.
 |
OXiGENE, Inc. |
 |
 |
 |
PROFILE |
 |
OXiGENE focuses on starving cancer tumors of oxygen. The firm's lead drug candidate, Combrestatin or CA4P, destroys blood vessels leading to tumors (known as antiangiogenesis), cutting off their supply of oxygen-rich blood needed to grow. It is developing CA4P with Bristol-Myers Squibb. Other candidates include Declopramide, which makes tumors more vulnerable to chemotherapy and radiation by inhibiting the DNA repair process, and Cordycepin, a leukemia treatment. Through joint venture ARCUS Therapetuics, OXiGENE and Peregrine Pharmaceuticals are exploring other antiangiogenesis programs. The firm also collaborates with universities in the US and Europe and other institutions to develop its drug pipeline.
COMPETITION |
 |
Boston Life Sciences, Inc. (BLSI)
ImClone Systems Incorporated (IMCL)
Matrix Pharmaceutical, Inc. (MATX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 1.70
1-Yr. Sales Growth: 30.8%
Employees: 15
Revenue per employee: $113,333.33
KEY PEOPLE |
 |
Bjorn Nordenvall
CEO
CONTACT INFO |
 |
321 Arsenal St.
Watertown, MA 02472
US
Phone: 617-673-7800
Fax: 617-924-9229
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |